NASDAQ:PTGX - Nasdaq - US74366E1029 - Common Stock - Currency: USD
NASDAQ:PTGX (5/5/2025, 9:57:56 AM)
44.92
-0.59 (-1.3%)
The current stock price of PTGX is 44.92 USD. In the past month the price decreased by -2.13%. In the past year, price increased by 74.43%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.13 | 347.60B | ||
AMGN | AMGEN INC | 13.3 | 148.46B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1726.41 | 128.71B | ||
GILD | GILEAD SCIENCES INC | 13.29 | 128.03B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 344.63 | 39.98B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.01B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.06B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.25B | ||
NTRA | NATERA INC | N/A | 21.28B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.14B | ||
BIIB | BIOGEN INC | 7.73 | 17.91B |
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 126 full-time employees. The company went IPO on 2016-08-11. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The firm also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
PROTAGONIST THERAPEUTICS INC
7707 Gateway Blvd Ste 140
Newark California CALIFORNIA 94560 US
CEO: Dinesh V. Patel
Employees: 126
Phone: 15104740170
The current stock price of PTGX is 44.92 USD. The price decreased by -1.3% in the last trading session.
The exchange symbol of PROTAGONIST THERAPEUTICS INC is PTGX and it is listed on the Nasdaq exchange.
PTGX stock is listed on the Nasdaq exchange.
16 analysts have analysed PTGX and the average price target is 70.83 USD. This implies a price increase of 57.69% is expected in the next year compared to the current price of 44.92. Check the PROTAGONIST THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PROTAGONIST THERAPEUTICS INC (PTGX) has a market capitalization of 2.78B USD. This makes PTGX a Mid Cap stock.
PROTAGONIST THERAPEUTICS INC (PTGX) currently has 126 employees.
PROTAGONIST THERAPEUTICS INC (PTGX) has a support level at 45.35 and a resistance level at 45.66. Check the full technical report for a detailed analysis of PTGX support and resistance levels.
The Revenue of PROTAGONIST THERAPEUTICS INC (PTGX) is expected to decline by -69.2% in the next year. Check the estimates tab for more information on the PTGX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PTGX does not pay a dividend.
PROTAGONIST THERAPEUTICS INC (PTGX) will report earnings on 2025-05-05, after the market close.
The PE ratio for PROTAGONIST THERAPEUTICS INC (PTGX) is 10.7. This is based on the reported non-GAAP earnings per share of 4.2 and the current share price of 44.92 USD. Check the full fundamental report for a full analysis of the valuation metrics for PTGX.
The outstanding short interest for PROTAGONIST THERAPEUTICS INC (PTGX) is 9.42% of its float. Check the ownership tab for more information on the PTGX short interest.
ChartMill assigns a technical rating of 8 / 10 to PTGX. When comparing the yearly performance of all stocks, PTGX is one of the better performing stocks in the market, outperforming 96.11% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to PTGX. PTGX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Over the last trailing twelve months PTGX reported a non-GAAP Earnings per Share(EPS) of 4.2. The EPS increased by 381.88% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 63.34% | ||
ROA | 36.95% | ||
ROE | 40.75% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to PTGX. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of -142.81% and a revenue growth -69.2% for PTGX